The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
Age range
18 Years – 64 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Haemagglutination Inhibition (HI) and Microneutralisation (MN) Antibody Titre Seroconversion Rate After the First Vaccination
Timeframe: Before and 21 days after the first vaccination
HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination
Timeframe: Before and 21 days after the second vaccination
Geometric Mean Fold Increase (GMFI) in the HI and MN Antibody Titre After the First Vaccination
Timeframe: Before and 21 days after the first vaccination
GMFI in the HI and MN Antibody Titer After the Second Vaccination
Timeframe: Before and 21 days after the second vaccination
Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination
Timeframe: 21 days after the first vaccination
Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination
Timeframe: 21 days after the second vaccination